Wearing Off Effect of OnabotulinumtoxinA Near the End of Treatment Cycle for Chronic Migraine: A 4-Year Clinical Experience
| Autor: | Fawad A. Khan, Anilkumar Chimakurthy, Mugilan Poongkunran, Michael Pepper, Alaa E. Mohammed |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Central sensitization Time Factors Migraine Disorders Tertiary Care Centers 03 medical and health sciences 0302 clinical medicine Chronic Migraine Quality of life Interquartile range Internal medicine medicine Humans 030212 general & internal medicine Patient Reported Outcome Measures Botulinum Toxins Type A Retrospective Studies Neck pain Analgesics Central Nervous System Sensitization business.industry Confounding Middle Aged medicine.disease Botulinum toxin Neurology Patient Satisfaction Chronic Disease Female Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery Anxiety disorder medicine.drug |
| Zdroj: | HeadacheReferences. 60(2) |
| ISSN: | 1526-4610 |
| Popis: | Introduction The injection interval for onabotulinumtoxinA (BoNTA) in the management of chronic migraine (CM) is 12 weeks (78-84 days). The aim of this study was to review patient-reported wearing off effect (WOE) of the therapeutic benefit of BoNTA near the end of the treatment cycle. We intended to describe the demographics of patients at baseline and compare groups of patients with multiple episodes of WOE. Methods We conducted a retrospective review of patients with CM who received uninterrupted BoNTA therapy from January 2014 to March 2018. The data from patient-reported WOE (worsening headache variables and neck pain) that occurred during the 4 weeks (28 days) prior to the scheduled re-injection of BoNTA for treatment cycles with injection interval ≤13 weeks and without obvious confounding factors were reviewed. Results We identified 98 eligible patients and analyzed 471 treatment cycles. Forty-three unique patients reported at least 1 occurrence of WOE. About 24/43 patients reported 1 WOE event and 19/43 patients reported ≥2 WOE events. Between the 2 groups, anxiety disorder and opioid use for headache were statistically significantly different. In the former group, the median interquartile range (IQR) dose of BoNTA was 165 (155, 175) units and the median IQR duration of the antinociceptive effect of BoNTA was 66.5 (63, 71.5) days. In the latter group, the median IQR dose of BoNTA was 167 (155, 173.3) units and the median IQR duration of the antinociceptive effect of BoNTA was 65.3 (62.5, 68.8) days. Up to 32% of these patients reported an increase in the use of abortive therapies to manage the symptoms of WOE. Discussion The primary goal of BoNTA in the treatment of CM is to mitigate the development of central sensitization. Since the 12-week injection paradigm may not provide sustained antinociceptive effect in all patients, it may account for the failure of response to BoNTA. Repeated occurrences of the WOE can potentially lead to medication overuse and impact quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text